rHuKGF decreased the requirement of IV opiods and total peripheral nutrition.

rHuKGF improved quality of life of pateitns with hematologic malignancies undergoing auto-PBPCT following TBI and chemotherapy conditioning.

rHuKGF was well tolerated.

Clinical/Scientific Implications:

This study shows Recombinant Human Kerotinocyte Growth Factore (rHuKGF) is effective in reducing the incidence of severe mucositis in association with high dose chemotherapy. There were no significant differences in the effectiveness of rHuKGF when looking at the two regimens used in this study. Further studies should define the optimal dosing of rHuKGF. There should also be future studies evalutating patients receiving combined chemotherapy and radiation therapy, as this is a population at high risk for developing mucositis.